APO Research
Talk to an analyst

APO RESEARCH · REPORT

Nonalcoholic Steatohepatitis Treatment

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global Nonalcoholic Steatohepatitis Treatment Market Outlook and Growth Opportunities 2026

31 December 2025197 pages

Choose your research edition.

Industry ResearchNonalcoholic Steatohepatitis Treatment Industry Research Report 2026124 pages · $2,950 USDIndustry Growth & TrendsGlobal Nonalcoholic Steatohepatitis Treatment Industry Growth and Trends Forecast to 2032102 pages · $3,450 USDMarket StructureGlobal Nonalcoholic Steatohepatitis Treatment Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032198 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Nonalcoholic Steatohepatitis Treatment Market Outlook and Growth Opportunities 2026197 pages · $4,250 USDMarket Analysis & ForecastGlobal Nonalcoholic Steatohepatitis Treatment Market Analysis and Forecast 2026-2032197 pages · $4,950 USD

Market perspective

The global Nonalcoholic Steatohepatitis Treatment market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for Nonalcoholic Steatohepatitis Treatment is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Nonalcoholic Steatohepatitis Treatment is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Nonalcoholic Steatohepatitis Treatment is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the Nonalcoholic Steatohepatitis Treatment market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the Nonalcoholic Steatohepatitis Treatment market include Arena Pharmaceuticals, Arisaph Pharmaceuticals, Cempra Pharmaceuticals, Galectin Therapeutics, Galmed Pharmaceuticals, Genfit, Gilead, Novo Nordisk and Vivus, among others. In 2025, the top three vendors together accounted for approximately % of global market revenue.

This report provides an overview of the global Nonalcoholic Steatohepatitis Treatment market in terms of revenue and gross margin, analyzing global market trends using historical revenue data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Nonalcoholic Steatohepatitis Treatment and market revenue by major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Nonalcoholic Steatohepatitis Treatment revenue, market share, and industry ranking for the main companies for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

Across the 2021-2026 period, the analysis compares revenue growth and profitability profiles by company, distinguishing participants with sustained expansion from those with more cyclical performance, and relates these patterns to differences in regional exposure, product portfolios, and application focus in the global Nonalcoholic Steatohepatitis Treatment market.

Nonalcoholic Steatohepatitis Treatment Segment by Company

Arena Pharmaceuticals

Arisaph Pharmaceuticals

Cempra Pharmaceuticals

Galectin Therapeutics

Galmed Pharmaceuticals

Genfit

Gilead

Novo Nordisk

Vivus

AstraZeneca

GSK

Roche

Nonalcoholic Steatohepatitis Treatment Segment by Type

Solid

Liquid

Nonalcoholic Steatohepatitis Treatment Segment by Application

Drug Store

Hospital

Hospital Pharmacy

Mail Order Pharmacy

Diagnostic Center

Specialized Clinic

Nonalcoholic Steatohepatitis Treatment Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Colombia

Middle East & Africa

Turkey

Saudi Arabia

UAE

Study Objectives

1. To analyze and research the global Nonalcoholic Steatohepatitis Treatment status and future forecast, involving, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the Nonalcoholic Steatohepatitis Treatment key companies, revenue, market share, and recent developments.

3. To split the Nonalcoholic Steatohepatitis Treatment breakdown data by regions, type, companies, and application.

4. To analyze the global and key regions Nonalcoholic Steatohepatitis Treatment market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Nonalcoholic Steatohepatitis Treatment significant trends, drivers, influence factors in global and regions.

6. To analyze Nonalcoholic Steatohepatitis Treatment competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Nonalcoholic Steatohepatitis Treatment market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Nonalcoholic Steatohepatitis Treatment and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Nonalcoholic Steatohepatitis Treatment.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, global total market size.

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Nonalcoholic Steatohepatitis Treatment industry.

Chapter 3: Detailed analysis of Nonalcoholic Steatohepatitis Treatment company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales value of Nonalcoholic Steatohepatitis Treatment in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of key country in the world.

Chapter 7: Sales value of Nonalcoholic Steatohepatitis Treatment in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.

Chapter 9: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Nonalcoholic Steatohepatitis Treatment Industry Trends Table 2. Nonalcoholic Steatohepatitis Treatment Industry Drivers Table 3. Nonalcoholic Steatohepatitis Treatment Industry Opportunities and Challenges Table 4. Nonalcoholic Steatohepatitis Treatment Industry Restraints Table 5. Global Nonalcoholic Steatohepatitis Treatment Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Nonalcoholic Steatohepatitis Treatment Revenue Share by Company (2021-2026) Table 7. Global Nonalcoholic Steatohepatitis Treatment Company Ranking, (2024-2026) & (US$ Million) Table 8. Global Nonalcoholic Steatohepatitis Treatment Key Company Manufacturing Base & Headquarters Table 9. Global Nonalcoholic Steatohepatitis Treatment Company, Product Type & Application Table 10. Global Nonalcoholic Steatohepatitis Treatment Company Establishment Date Table 11. Global Company Market Concentration Ratio (CR5 and HHI) Table 12. Global Nonalcoholic Steatohepatitis Treatment by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 13. Mergers & Acquisitions, Expansion Table 14. Significant Companies of Solid Table 15. Significant Companies of Liquid Table 16. Global Nonalcoholic Steatohepatitis Treatment Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 17. Global Nonalcoholic Steatohepatitis Treatment Sales Value by Type (2021-2026) & (US$ Million) Table 18. Global Nonalcoholic Steatohepatitis Treatment Sales Value by Type (2027-2032) & (US$ Million) Table 19. Global Nonalcoholic Steatohepatitis Treatment Sales Value Share by Type (2021-2026) Table 20. Global Nonalcoholic Steatohepatitis Treatment Sales Value Share by Type (2027-2032) Table 21. Significant Companies of Drug Store Table 22. Significant Companies of Hospital Table 23. Significant Companies of Hospital Pharmacy Table 24. Significant Companies of Mail Order Pharmacy Table 25. Significant Companies of Diagnostic Center Table 26. Significant Companies of Specialized Clinic Table 27. Global Nonalcoholic Steatohepatitis Treatment Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 28. Global Nonalcoholic Steatohepatitis Treatment Sales Value by Application (2021-2026) & (US$ Million) Table 29. Global Nonalcoholic Steatohepatitis Treatment Sales Value by Application (2027-2032) & (US$ Million) Table 30. Global Nonalcoholic Steatohepatitis Treatment Sales Value Share by Application (2021-2026) Table 31. Global Nonalcoholic Steatohepatitis Treatment Sales Value Share by Application (2027-2032) Table 32. Global Nonalcoholic Steatohepatitis Treatment Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 33. Global Nonalcoholic Steatohepatitis Treatment Sales Value by Region (2021-2026) & (US$ Million) Table 34. Global Nonalcoholic Steatohepatitis Treatment Sales Value Share by Region (2021-2026) Table 35. Global Nonalcoholic Steatohepatitis Treatment Sales Value by Region (2027-2032) & (US$ Million) Table 36. Global Nonalcoholic Steatohepatitis Treatment Sales Value Share by Region (2027-2032) Table 37. Global Nonalcoholic Steatohepatitis Treatment Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 38. Global Nonalcoholic Steatohepatitis Treatment Sales Value by Country (2021-2026) & (US$ Million) Table 39. Global Nonalcoholic Steatohepatitis Treatment Sales Value Market Share by Country (2021-2026) Table 40. Global Nonalcoholic Steatohepatitis Treatment Sales Value by Country (2027-2032) & (US$ Million) Table 41. Global Nonalcoholic Steatohepatitis Treatment Sales Value Market Share by Country (2027-2032) Table 42. Arena Pharmaceuticals Company Information Table 43. Arena Pharmaceuticals Business Overview Table 44. Arena Pharmaceuticals Nonalcoholic Steatohepatitis Treatment Revenue (US$ Million) and Gross Margin (2021-2026) Table 45. Arena Pharmaceuticals Nonalcoholic Steatohepatitis Treatment Product Portfolio Table 46. Arena Pharmaceuticals Recent Development Table 47. Arisaph Pharmaceuticals Company Information Table 48. Arisaph Pharmaceuticals Business Overview Table 49. Arisaph Pharmaceuticals Nonalcoholic Steatohepatitis Treatment Revenue (US$ Million) and Gross Margin (2021-2026) Table 50. Arisaph Pharmaceuticals Nonalcoholic Steatohepatitis Treatment Product Portfolio Table 51. Arisaph Pharmaceuticals Recent Development Table 52. Cempra Pharmaceuticals Company Information Table 53. Cempra Pharmaceuticals Business Overview Table 54. Cempra Pharmaceuticals Nonalcoholic Steatohepatitis Treatment Revenue (US$ Million) and Gross Margin (2021-2026) Table 55. Cempra Pharmaceuticals Nonalcoholic Steatohepatitis Treatment Product Portfolio Table 56. Cempra Pharmaceuticals Recent Development Table 57. Galectin Therapeutics Company Information Table 58. Galectin Therapeutics Business Overview Table 59. Galectin Therapeutics Nonalcoholic Steatohepatitis Treatment Revenue (US$ Million) and Gross Margin (2021-2026) Table 60. Galectin Therapeutics Nonalcoholic Steatohepatitis Treatment Product Portfolio Table 61. Galectin Therapeutics Recent Development Table 62. Galmed Pharmaceuticals Company Information Table 63. Galmed Pharmaceuticals Business Overview Table 64. Galmed Pharmaceuticals Nonalcoholic Steatohepatitis Treatment Revenue (US$ Million) and Gross Margin (2021-2026) Table 65. Galmed Pharmaceuticals Nonalcoholic Steatohepatitis Treatment Product Portfolio Table 66. Galmed Pharmaceuticals Recent Development Table 67. Genfit Company Information Table 68. Genfit Business Overview Table 69. Genfit Nonalcoholic Steatohepatitis Treatment Revenue (US$ Million) and Gross Margin (2021-2026) Table 70. Genfit Nonalcoholic Steatohepatitis Treatment Product Portfolio Table 71. Genfit Recent Development Table 72. Gilead Company Information Table 73. Gilead Business Overview Table 74. Gilead Nonalcoholic Steatohepatitis Treatment Revenue (US$ Million) and Gross Margin (2021-2026) Table 75. Gilead Nonalcoholic Steatohepatitis Treatment Product Portfolio Table 76. Gilead Recent Development Table 77. Novo Nordisk Company Information Table 78. Novo Nordisk Business Overview Table 79. Novo Nordisk Nonalcoholic Steatohepatitis Treatment Revenue (US$ Million) and Gross Margin (2021-2026) Table 80. Novo Nordisk Nonalcoholic Steatohepatitis Treatment Product Portfolio Table 81. Novo Nordisk Recent Development Table 82. Vivus Company Information Table 83. Vivus Business Overview Table 84. Vivus Nonalcoholic Steatohepatitis Treatment Revenue (US$ Million) and Gross Margin (2021-2026) Table 85. Vivus Nonalcoholic Steatohepatitis Treatment Product Portfolio Table 86. Vivus Recent Development Table 87. AstraZeneca Company Information Table 88. AstraZeneca Business Overview Table 89. AstraZeneca Nonalcoholic Steatohepatitis Treatment Revenue (US$ Million) and Gross Margin (2021-2026) Table 90. AstraZeneca Nonalcoholic Steatohepatitis Treatment Product Portfolio Table 91. AstraZeneca Recent Development Table 92. GSK Company Information Table 93. GSK Business Overview Table 94. GSK Nonalcoholic Steatohepatitis Treatment Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 95. GSK Nonalcoholic Steatohepatitis Treatment Product Portfolio Table 96. GSK Recent Development Table 97. Roche Company Information Table 98. Roche Business Overview Table 99. Roche Nonalcoholic Steatohepatitis Treatment Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 100. Roche Nonalcoholic Steatohepatitis Treatment Product Portfolio Table 101. Roche Recent Development Table 102. Research Programs/Design for This Report Table 103. Authors List of This Report Table 104. Secondary Sources Table 105. Primary Sources List of Figures Figure 1. Nonalcoholic Steatohepatitis Treatment Product Image Figure 2. Global Nonalcoholic Steatohepatitis Treatment Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Nonalcoholic Steatohepatitis Treatment Market Size (2021-2032) & (US$ Million) Figure 4. Global Nonalcoholic Steatohepatitis Treatment Company Revenue Ranking in 2025 (US$ Million) Figure 5. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 6. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 7. Solid Image Figure 8. Liquid Image Figure 9. Global Nonalcoholic Steatohepatitis Treatment Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 10. Global Nonalcoholic Steatohepatitis Treatment Sales Value Share 2021 VS 2025 VS 2032 Figure 11. Global Nonalcoholic Steatohepatitis Treatment Sales Value Share by Type (2021-2032) Figure 12. Drug Store Image Figure 13. Hospital Image Figure 14. Hospital Pharmacy Image Figure 15. Mail Order Pharmacy Image Figure 16. Diagnostic Center Image Figure 17. Specialized Clinic Image Figure 18. Global Nonalcoholic Steatohepatitis Treatment Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 19. Global Nonalcoholic Steatohepatitis Treatment Sales Value Share 2021 VS 2025 VS 2032 Figure 20. Global Nonalcoholic Steatohepatitis Treatment Sales Value Share by Application (2021-2032) Figure 21. Global Nonalcoholic Steatohepatitis Treatment Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 22. Global Nonalcoholic Steatohepatitis Treatment Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 23. North America Nonalcoholic Steatohepatitis Treatment Sales Value (2021-2032) & (US$ Million) Figure 24. North America Nonalcoholic Steatohepatitis Treatment Sales Value Share by Country (%), 2025 VS 2032 Figure 25. Europe Nonalcoholic Steatohepatitis Treatment Sales Value (2021-2032) & (US$ Million) Figure 26. Europe Nonalcoholic Steatohepatitis Treatment Sales Value Share by Country (%), 2025 VS 2032 Figure 27. Asia-Pacific Nonalcoholic Steatohepatitis Treatment Sales Value (2021-2032) & (US$ Million) Figure 28. Asia-Pacific Nonalcoholic Steatohepatitis Treatment Sales Value Share by Country (%), 2025 VS 2032 Figure 29. South America Nonalcoholic Steatohepatitis Treatment Sales Value (2021-2032) & (US$ Million) Figure 30. South America Nonalcoholic Steatohepatitis Treatment Sales Value Share by Country (%), 2025 VS 2032 Figure 31. Middle East & Africa Nonalcoholic Steatohepatitis Treatment Sales Value (2021-2032) & (US$ Million) Figure 32. Middle East & Africa Nonalcoholic Steatohepatitis Treatment Sales Value Share by Country (%), 2025 VS 2032 Figure 33. USA Nonalcoholic Steatohepatitis Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 34. USA Nonalcoholic Steatohepatitis Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 35. USA Nonalcoholic Steatohepatitis Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 36. Canada Nonalcoholic Steatohepatitis Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 37. Canada Nonalcoholic Steatohepatitis Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 38. Canada Nonalcoholic Steatohepatitis Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 39. Mexico Nonalcoholic Steatohepatitis Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 40. Mexico Nonalcoholic Steatohepatitis Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 41. Mexico Nonalcoholic Steatohepatitis Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 42. Germany Nonalcoholic Steatohepatitis Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 43. Germany Nonalcoholic Steatohepatitis Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 44. Germany Nonalcoholic Steatohepatitis Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 45. France Nonalcoholic Steatohepatitis Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 46. France Nonalcoholic Steatohepatitis Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 47. France Nonalcoholic Steatohepatitis Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 48. U.K. Nonalcoholic Steatohepatitis Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 49. U.K. Nonalcoholic Steatohepatitis Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 50. U.K. Nonalcoholic Steatohepatitis Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 51. Italy Nonalcoholic Steatohepatitis Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 52. Italy Nonalcoholic Steatohepatitis Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 53. Italy Nonalcoholic Steatohepatitis Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 54. Spain Nonalcoholic Steatohepatitis Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 55. Spain Nonalcoholic Steatohepatitis Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 56. Spain Nonalcoholic Steatohepatitis Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 57. Russia Nonalcoholic Steatohepatitis Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 58. Russia Nonalcoholic Steatohepatitis Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 59. Russia Nonalcoholic Steatohepatitis Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 60. Netherlands Nonalcoholic Steatohepatitis Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 61. Netherlands Nonalcoholic Steatohepatitis Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 62. Netherlands Nonalcoholic Steatohepatitis Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 63. Nordic Countries Nonalcoholic Steatohepatitis Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 64. Nordic Countries Nonalcoholic Steatohepatitis Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 65. Nordic Countries Nonalcoholic Steatohepatitis Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 66. China Nonalcoholic Steatohepatitis Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 67. China Nonalcoholic Steatohepatitis Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 68. China Nonalcoholic Steatohepatitis Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 69. Japan Nonalcoholic Steatohepatitis Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 70. Japan Nonalcoholic Steatohepatitis Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 71. Japan Nonalcoholic Steatohepatitis Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 72. South Korea Nonalcoholic Steatohepatitis Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 73. South Korea Nonalcoholic Steatohepatitis Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 74. South Korea Nonalcoholic Steatohepatitis Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 75. India Nonalcoholic Steatohepatitis Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 76. India Nonalcoholic Steatohepatitis Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 77. India Nonalcoholic Steatohepatitis Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 78. Australia Nonalcoholic Steatohepatitis Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 79. Australia Nonalcoholic Steatohepatitis Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 80. Australia Nonalcoholic Steatohepatitis Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 81. Southeast Asia Nonalcoholic Steatohepatitis Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 82. Southeast Asia Nonalcoholic Steatohepatitis Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 83. Southeast Asia Nonalcoholic Steatohepatitis Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 84. Brazil Nonalcoholic Steatohepatitis Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 85. Brazil Nonalcoholic Steatohepatitis Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 86. Brazil Nonalcoholic Steatohepatitis Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 87. Argentina Nonalcoholic Steatohepatitis Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 88. Argentina Nonalcoholic Steatohepatitis Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 89. Argentina Nonalcoholic Steatohepatitis Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 90. Chile Nonalcoholic Steatohepatitis Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 91. Chile Nonalcoholic Steatohepatitis Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 92. Chile Nonalcoholic Steatohepatitis Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 93. Colombia Nonalcoholic Steatohepatitis Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 94. Colombia Nonalcoholic Steatohepatitis Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 95. Colombia Nonalcoholic Steatohepatitis Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 96. Peru Nonalcoholic Steatohepatitis Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 97. Peru Nonalcoholic Steatohepatitis Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 98. Peru Nonalcoholic Steatohepatitis Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 99. Saudi Arabia Nonalcoholic Steatohepatitis Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 100. Saudi Arabia Nonalcoholic Steatohepatitis Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 101. Saudi Arabia Nonalcoholic Steatohepatitis Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 102. Israel Nonalcoholic Steatohepatitis Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 103. Israel Nonalcoholic Steatohepatitis Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 104. Israel Nonalcoholic Steatohepatitis Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 105. UAE Nonalcoholic Steatohepatitis Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 106. UAE Nonalcoholic Steatohepatitis Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 107. UAE Nonalcoholic Steatohepatitis Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 108. Turkey Nonalcoholic Steatohepatitis Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 109. Turkey Nonalcoholic Steatohepatitis Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 110. Turkey Nonalcoholic Steatohepatitis Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 111. Iran Nonalcoholic Steatohepatitis Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 112. Iran Nonalcoholic Steatohepatitis Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 113. Iran Nonalcoholic Steatohepatitis Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 114. Egypt Nonalcoholic Steatohepatitis Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 115. Egypt Nonalcoholic Steatohepatitis Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 116. Egypt Nonalcoholic Steatohepatitis Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 117. Years Considered Figure 118. Research Process Figure 119. Key Executives Interviewed

Scope & coverage.

Types
  • Solid
  • Liquid
Applications
  • Drug Store
  • Hospital
  • Hospital Pharmacy
  • Mail Order Pharmacy
  • Diagnostic Center
  • Specialized Clinic
Companies covered
  • Arena Pharmaceuticals
  • Arisaph Pharmaceuticals
  • Cempra Pharmaceuticals
  • Galectin Therapeutics
  • Galmed Pharmaceuticals
  • Genfit
  • Gilead
  • Novo Nordisk
  • Vivus
  • AstraZeneca
  • GSK
  • Roche

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Nonalcoholic Steatohepatitis Treatment Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global Nonalcoholic Steatohepatitis Treatment Market Size (2021-2032)
  4. 1.4 Assumptions and Limitations
  5. 1.5 Study Goals and Objectives
2 Nonalcoholic Steatohepatitis Treatment Market Dynamics
  1. 2.1 Nonalcoholic Steatohepatitis Treatment Industry Trends
  2. 2.2 Nonalcoholic Steatohepatitis Treatment Industry Drivers
  3. 2.3 Nonalcoholic Steatohepatitis Treatment Industry Opportunities and Challenges
  4. 2.4 Nonalcoholic Steatohepatitis Treatment Industry Restraints
3 Nonalcoholic Steatohepatitis Treatment Market by Company
  1. 3.1 Global Nonalcoholic Steatohepatitis Treatment Company Revenue Ranking in 2025
  2. 3.2 Global Nonalcoholic Steatohepatitis Treatment Revenue by Company (2021-2026)
  3. 3.3 Global Nonalcoholic Steatohepatitis Treatment Company Ranking (2024-2026)
  4. 3.4 Global Nonalcoholic Steatohepatitis Treatment Company Manufacturing Base and Headquarters
  5. 3.5 Global Nonalcoholic Steatohepatitis Treatment Company Product Type and Application
  6. 3.6 Global Nonalcoholic Steatohepatitis Treatment Company Establishment Date
  7. 3.7 Market Competitive Analysis
  8. 3.7.1 Global Nonalcoholic Steatohepatitis Treatment Market Concentration Ratio (CR5 and HHI)
  9. 3.7.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  10. 3.7.3 2025 Nonalcoholic Steatohepatitis Treatment Tier 1, Tier 2, and Tier 3 Companies
  11. 3.8 Mergers and Acquisitions Expansion
4 Nonalcoholic Steatohepatitis Treatment Market by Type
  1. 4.1 Nonalcoholic Steatohepatitis Treatment Type Introduction
  2. 4.1.1 Solid
  3. 4.1.2 Liquid
  4. 4.2 Global Nonalcoholic Steatohepatitis Treatment Sales Value by Type
  5. 4.2.1 Global Nonalcoholic Steatohepatitis Treatment Sales Value by Type (2021 VS 2025 VS 2032)
  6. 4.2.2 Global Nonalcoholic Steatohepatitis Treatment Sales Value by Type (2021-2032)
  7. 4.2.3 Global Nonalcoholic Steatohepatitis Treatment Sales Value Share by Type (2021-2032)
5 Nonalcoholic Steatohepatitis Treatment Market by Application
  1. 5.1 Nonalcoholic Steatohepatitis Treatment Application Introduction
  2. 5.1.1 Drug Store
  3. 5.1.2 Hospital
  4. 5.1.3 Hospital Pharmacy
  5. 5.1.4 Mail Order Pharmacy
  6. 5.1.5 Diagnostic Center
  7. 5.1.6 Specialized Clinic
  8. 5.2 Global Nonalcoholic Steatohepatitis Treatment Sales Value by Application
  9. 5.2.1 Global Nonalcoholic Steatohepatitis Treatment Sales Value by Application (2021 VS 2025 VS 2032)
  10. 5.2.2 Global Nonalcoholic Steatohepatitis Treatment Sales Value by Application (2021-2032)
  11. 5.2.3 Global Nonalcoholic Steatohepatitis Treatment Sales Value Share by Application (2021-2032)
6 Nonalcoholic Steatohepatitis Treatment Regional Value Analysis
  1. 6.1 Global Nonalcoholic Steatohepatitis Treatment Sales Value by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Nonalcoholic Steatohepatitis Treatment Sales Value by Region (2021-2032)
  3. 6.2.1 Global Nonalcoholic Steatohepatitis Treatment Sales Value by Region: 2021-2026
  4. 6.2.2 Global Nonalcoholic Steatohepatitis Treatment Sales Value by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America Nonalcoholic Steatohepatitis Treatment Sales Value (2021-2032)
  7. 6.3.2 North America Nonalcoholic Steatohepatitis Treatment Sales Value Share by Country, 2025 VS 2032
  8. 6.4 Europe
  9. 6.4.1 Europe Nonalcoholic Steatohepatitis Treatment Sales Value (2021-2032)
  10. 6.4.2 Europe Nonalcoholic Steatohepatitis Treatment Sales Value Share by Country, 2025 VS 2032
  11. 6.5 Asia-Pacific
  12. 6.5.1 Asia-Pacific Nonalcoholic Steatohepatitis Treatment Sales Value (2021-2032)
  13. 6.5.2 Asia-Pacific Nonalcoholic Steatohepatitis Treatment Sales Value Share by Country, 2025 VS 2032
  14. 6.6 South America
  15. 6.6.1 South America Nonalcoholic Steatohepatitis Treatment Sales Value (2021-2032)
  16. 6.6.2 South America Nonalcoholic Steatohepatitis Treatment Sales Value Share by Country, 2025 VS 2032
  17. 6.7 Middle East & Africa
  18. 6.7.1 Middle East & Africa Nonalcoholic Steatohepatitis Treatment Sales Value (2021-2032)
  19. 6.7.2 Middle East & Africa Nonalcoholic Steatohepatitis Treatment Sales Value Share by Country, 2025 VS 2032
7 Nonalcoholic Steatohepatitis Treatment Country-level Value Analysis
  1. 7.1 Global Nonalcoholic Steatohepatitis Treatment Sales Value by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Nonalcoholic Steatohepatitis Treatment Sales Value by Country (2021-2032)
  3. 7.2.1 Global Nonalcoholic Steatohepatitis Treatment Sales Value by Country (2021-2026)
  4. 7.2.2 Global Nonalcoholic Steatohepatitis Treatment Sales Value by Country (2027-2032)
  5. 7.3 USA
  6. 7.3.1 USA Nonalcoholic Steatohepatitis Treatment Sales Value Growth Rate (2021-2032)
  7. 7.3.2 USA Nonalcoholic Steatohepatitis Treatment Sales Value Share by Type, 2025 VS 2032
  8. 7.3.3 USA Nonalcoholic Steatohepatitis Treatment Sales Value Share by Application, 2025 VS 2032
  9. 7.4 Canada
  10. 7.4.1 Canada Nonalcoholic Steatohepatitis Treatment Sales Value Growth Rate (2021-2032)
  11. 7.4.2 Canada Nonalcoholic Steatohepatitis Treatment Sales Value Share by Type, 2025 VS 2032
  12. 7.4.3 Canada Nonalcoholic Steatohepatitis Treatment Sales Value Share by Application, 2025 VS 2032
  13. 7.5 Mexico
  14. 7.5.1 Mexico Nonalcoholic Steatohepatitis Treatment Sales Value Growth Rate (2021-2032)
  15. 7.5.2 Mexico Nonalcoholic Steatohepatitis Treatment Sales Value Share by Type, 2025 VS 2032
  16. 7.5.3 Mexico Nonalcoholic Steatohepatitis Treatment Sales Value Share by Application, 2025 VS 2032
  17. 7.6 Germany
  18. 7.6.1 Germany Nonalcoholic Steatohepatitis Treatment Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Germany Nonalcoholic Steatohepatitis Treatment Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Germany Nonalcoholic Steatohepatitis Treatment Sales Value Share by Application, 2025 VS 2032
  21. 7.7 France
  22. 7.7.1 France Nonalcoholic Steatohepatitis Treatment Sales Value Growth Rate (2021-2032)
  23. 7.7.2 France Nonalcoholic Steatohepatitis Treatment Sales Value Share by Type, 2025 VS 2032
  24. 7.7.3 France Nonalcoholic Steatohepatitis Treatment Sales Value Share by Application, 2025 VS 2032
  25. 7.8 U.K.
  26. 7.8.1 U.K. Nonalcoholic Steatohepatitis Treatment Sales Value Growth Rate (2021-2032)
  27. 7.8.2 U.K. Nonalcoholic Steatohepatitis Treatment Sales Value Share by Type, 2025 VS 2032
  28. 7.8.3 U.K. Nonalcoholic Steatohepatitis Treatment Sales Value Share by Application, 2025 VS 2032
  29. 7.9 Italy
  30. 7.9.1 Italy Nonalcoholic Steatohepatitis Treatment Sales Value Growth Rate (2021-2032)
  31. 7.9.2 Italy Nonalcoholic Steatohepatitis Treatment Sales Value Share by Type, 2025 VS 2032
  32. 7.9.3 Italy Nonalcoholic Steatohepatitis Treatment Sales Value Share by Application, 2025 VS 2032
  33. 7.10 Spain
  34. 7.10.1 Spain Nonalcoholic Steatohepatitis Treatment Sales Value Growth Rate (2021-2032)
  35. 7.10.2 Spain Nonalcoholic Steatohepatitis Treatment Sales Value Share by Type, 2025 VS 2032
  36. 7.10.3 Spain Nonalcoholic Steatohepatitis Treatment Sales Value Share by Application, 2025 VS 2032
  37. 7.11 Russia
  38. 7.11.1 Russia Nonalcoholic Steatohepatitis Treatment Sales Value Growth Rate (2021-2032)
  39. 7.11.2 Russia Nonalcoholic Steatohepatitis Treatment Sales Value Share by Type, 2025 VS 2032
  40. 7.11.3 Russia Nonalcoholic Steatohepatitis Treatment Sales Value Share by Application, 2025 VS 2032
  41. 7.12 Netherlands
  42. 7.12.1 Netherlands Nonalcoholic Steatohepatitis Treatment Sales Value Growth Rate (2021-2032)
  43. 7.12.2 Netherlands Nonalcoholic Steatohepatitis Treatment Sales Value Share by Type, 2025 VS 2032
  44. 7.12.3 Netherlands Nonalcoholic Steatohepatitis Treatment Sales Value Share by Application, 2025 VS 2032
  45. 7.13 Nordic Countries
  46. 7.13.1 Nordic Countries Nonalcoholic Steatohepatitis Treatment Sales Value Growth Rate (2021-2032)
  47. 7.13.2 Nordic Countries Nonalcoholic Steatohepatitis Treatment Sales Value Share by Type, 2025 VS 2032
  48. 7.13.3 Nordic Countries Nonalcoholic Steatohepatitis Treatment Sales Value Share by Application, 2025 VS 2032
  49. 7.14 China
  50. 7.14.1 China Nonalcoholic Steatohepatitis Treatment Sales Value Growth Rate (2021-2032)
  51. 7.14.2 China Nonalcoholic Steatohepatitis Treatment Sales Value Share by Type, 2025 VS 2032
  52. 7.14.3 China Nonalcoholic Steatohepatitis Treatment Sales Value Share by Application, 2025 VS 2032
  53. 7.15 Japan
  54. 7.15.1 Japan Nonalcoholic Steatohepatitis Treatment Sales Value Growth Rate (2021-2032)
  55. 7.15.2 Japan Nonalcoholic Steatohepatitis Treatment Sales Value Share by Type, 2025 VS 2032
  56. 7.15.3 Japan Nonalcoholic Steatohepatitis Treatment Sales Value Share by Application, 2025 VS 2032
  57. 7.16 South Korea
  58. 7.16.1 South Korea Nonalcoholic Steatohepatitis Treatment Sales Value Growth Rate (2021-2032)
  59. 7.16.2 South Korea Nonalcoholic Steatohepatitis Treatment Sales Value Share by Type, 2025 VS 2032
  60. 7.16.3 South Korea Nonalcoholic Steatohepatitis Treatment Sales Value Share by Application, 2025 VS 2032
  61. 7.17 India
  62. 7.17.1 India Nonalcoholic Steatohepatitis Treatment Sales Value Growth Rate (2021-2032)
  63. 7.17.2 India Nonalcoholic Steatohepatitis Treatment Sales Value Share by Type, 2025 VS 2032
  64. 7.17.3 India Nonalcoholic Steatohepatitis Treatment Sales Value Share by Application, 2025 VS 2032
  65. 7.18 Australia
  66. 7.18.1 Australia Nonalcoholic Steatohepatitis Treatment Sales Value Growth Rate (2021-2032)
  67. 7.18.2 Australia Nonalcoholic Steatohepatitis Treatment Sales Value Share by Type, 2025 VS 2032
  68. 7.18.3 Australia Nonalcoholic Steatohepatitis Treatment Sales Value Share by Application, 2025 VS 2032
  69. 7.19 Southeast Asia
  70. 7.19.1 Southeast Asia Nonalcoholic Steatohepatitis Treatment Sales Value Growth Rate (2021-2032)
  71. 7.19.2 Southeast Asia Nonalcoholic Steatohepatitis Treatment Sales Value Share by Type, 2025 VS 2032
  72. 7.19.3 Southeast Asia Nonalcoholic Steatohepatitis Treatment Sales Value Share by Application, 2025 VS 2032
  73. 7.20 Brazil
  74. 7.20.1 Brazil Nonalcoholic Steatohepatitis Treatment Sales Value Growth Rate (2021-2032)
  75. 7.20.2 Brazil Nonalcoholic Steatohepatitis Treatment Sales Value Share by Type, 2025 VS 2032
  76. 7.20.3 Brazil Nonalcoholic Steatohepatitis Treatment Sales Value Share by Application, 2025 VS 2032
  77. 7.21 Argentina
  78. 7.21.1 Argentina Nonalcoholic Steatohepatitis Treatment Sales Value Growth Rate (2021-2032)
  79. 7.21.2 Argentina Nonalcoholic Steatohepatitis Treatment Sales Value Share by Type, 2025 VS 2032
  80. 7.21.3 Argentina Nonalcoholic Steatohepatitis Treatment Sales Value Share by Application, 2025 VS 2032
  81. 7.22 Chile
  82. 7.22.1 Chile Nonalcoholic Steatohepatitis Treatment Sales Value Growth Rate (2021-2032)
  83. 7.22.2 Chile Nonalcoholic Steatohepatitis Treatment Sales Value Share by Type, 2025 VS 2032
  84. 7.22.3 Chile Nonalcoholic Steatohepatitis Treatment Sales Value Share by Application, 2025 VS 2032
  85. 7.23 Colombia
  86. 7.23.1 Colombia Nonalcoholic Steatohepatitis Treatment Sales Value Growth Rate (2021-2032)
  87. 7.23.2 Colombia Nonalcoholic Steatohepatitis Treatment Sales Value Share by Type, 2025 VS 2032
  88. 7.23.3 Colombia Nonalcoholic Steatohepatitis Treatment Sales Value Share by Application, 2025 VS 2032
  89. 7.24 Peru
  90. 7.24.1 Peru Nonalcoholic Steatohepatitis Treatment Sales Value Growth Rate (2021-2032)
  91. 7.24.2 Peru Nonalcoholic Steatohepatitis Treatment Sales Value Share by Type, 2025 VS 2032
  92. 7.24.3 Peru Nonalcoholic Steatohepatitis Treatment Sales Value Share by Application, 2025 VS 2032
  93. 7.25 Saudi Arabia
  94. 7.25.1 Saudi Arabia Nonalcoholic Steatohepatitis Treatment Sales Value Growth Rate (2021-2032)
  95. 7.25.2 Saudi Arabia Nonalcoholic Steatohepatitis Treatment Sales Value Share by Type, 2025 VS 2032
  96. 7.25.3 Saudi Arabia Nonalcoholic Steatohepatitis Treatment Sales Value Share by Application, 2025 VS 2032
  97. 7.26 Israel
  98. 7.26.1 Israel Nonalcoholic Steatohepatitis Treatment Sales Value Growth Rate (2021-2032)
  99. 7.26.2 Israel Nonalcoholic Steatohepatitis Treatment Sales Value Share by Type, 2025 VS 2032
  100. 7.26.3 Israel Nonalcoholic Steatohepatitis Treatment Sales Value Share by Application, 2025 VS 2032
  101. 7.27 UAE
  102. 7.27.1 UAE Nonalcoholic Steatohepatitis Treatment Sales Value Growth Rate (2021-2032)
  103. 7.27.2 UAE Nonalcoholic Steatohepatitis Treatment Sales Value Share by Type, 2025 VS 2032
  104. 7.27.3 UAE Nonalcoholic Steatohepatitis Treatment Sales Value Share by Application, 2025 VS 2032
  105. 7.28 Turkey
  106. 7.28.1 Turkey Nonalcoholic Steatohepatitis Treatment Sales Value Growth Rate (2021-2032)
  107. 7.28.2 Turkey Nonalcoholic Steatohepatitis Treatment Sales Value Share by Type, 2025 VS 2032
  108. 7.28.3 Turkey Nonalcoholic Steatohepatitis Treatment Sales Value Share by Application, 2025 VS 2032
  109. 7.29 Iran
  110. 7.29.1 Iran Nonalcoholic Steatohepatitis Treatment Sales Value Growth Rate (2021-2032)
  111. 7.29.2 Iran Nonalcoholic Steatohepatitis Treatment Sales Value Share by Type, 2025 VS 2032
  112. 7.29.3 Iran Nonalcoholic Steatohepatitis Treatment Sales Value Share by Application, 2025 VS 2032
  113. 7.30 Egypt
  114. 7.30.1 Egypt Nonalcoholic Steatohepatitis Treatment Sales Value Growth Rate (2021-2032)
  115. 7.30.2 Egypt Nonalcoholic Steatohepatitis Treatment Sales Value Share by Type, 2025 VS 2032
  116. 7.30.3 Egypt Nonalcoholic Steatohepatitis Treatment Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Arena Pharmaceuticals
  2. 8.1.1 Arena Pharmaceuticals Company Information
  3. 8.1.2 Arena Pharmaceuticals Business Overview
  4. 8.1.3 Arena Pharmaceuticals Nonalcoholic Steatohepatitis Treatment Revenue and Gross Margin (2021-2026)
  5. 8.1.4 Arena Pharmaceuticals Nonalcoholic Steatohepatitis Treatment Product Portfolio
  6. 8.1.5 Arena Pharmaceuticals Recent Developments
  7. 8.2 Arisaph Pharmaceuticals
  8. 8.2.1 Arisaph Pharmaceuticals Company Information
  9. 8.2.2 Arisaph Pharmaceuticals Business Overview
  10. 8.2.3 Arisaph Pharmaceuticals Nonalcoholic Steatohepatitis Treatment Revenue and Gross Margin (2021-2026)
  11. 8.2.4 Arisaph Pharmaceuticals Nonalcoholic Steatohepatitis Treatment Product Portfolio
  12. 8.2.5 Arisaph Pharmaceuticals Recent Developments
  13. 8.3 Cempra Pharmaceuticals
  14. 8.3.1 Cempra Pharmaceuticals Company Information
  15. 8.3.2 Cempra Pharmaceuticals Business Overview
  16. 8.3.3 Cempra Pharmaceuticals Nonalcoholic Steatohepatitis Treatment Revenue and Gross Margin (2021-2026)
  17. 8.3.4 Cempra Pharmaceuticals Nonalcoholic Steatohepatitis Treatment Product Portfolio
  18. 8.3.5 Cempra Pharmaceuticals Recent Developments
  19. 8.4 Galectin Therapeutics
  20. 8.4.1 Galectin Therapeutics Company Information
  21. 8.4.2 Galectin Therapeutics Business Overview
  22. 8.4.3 Galectin Therapeutics Nonalcoholic Steatohepatitis Treatment Revenue and Gross Margin (2021-2026)
  23. 8.4.4 Galectin Therapeutics Nonalcoholic Steatohepatitis Treatment Product Portfolio
  24. 8.4.5 Galectin Therapeutics Recent Developments
  25. 8.5 Galmed Pharmaceuticals
  26. 8.5.1 Galmed Pharmaceuticals Company Information
  27. 8.5.2 Galmed Pharmaceuticals Business Overview
  28. 8.5.3 Galmed Pharmaceuticals Nonalcoholic Steatohepatitis Treatment Revenue and Gross Margin (2021-2026)
  29. 8.5.4 Galmed Pharmaceuticals Nonalcoholic Steatohepatitis Treatment Product Portfolio
  30. 8.5.5 Galmed Pharmaceuticals Recent Developments
  31. 8.6 Genfit
  32. 8.6.1 Genfit Company Information
  33. 8.6.2 Genfit Business Overview
  34. 8.6.3 Genfit Nonalcoholic Steatohepatitis Treatment Revenue and Gross Margin (2021-2026)
  35. 8.6.4 Genfit Nonalcoholic Steatohepatitis Treatment Product Portfolio
  36. 8.6.5 Genfit Recent Developments
  37. 8.7 Gilead
  38. 8.7.1 Gilead Company Information
  39. 8.7.2 Gilead Business Overview
  40. 8.7.3 Gilead Nonalcoholic Steatohepatitis Treatment Revenue and Gross Margin (2021-2026)
  41. 8.7.4 Gilead Nonalcoholic Steatohepatitis Treatment Product Portfolio
  42. 8.7.5 Gilead Recent Developments
  43. 8.8 Novo Nordisk
  44. 8.8.1 Novo Nordisk Company Information
  45. 8.8.2 Novo Nordisk Business Overview
  46. 8.8.3 Novo Nordisk Nonalcoholic Steatohepatitis Treatment Revenue and Gross Margin (2021-2026)
  47. 8.8.4 Novo Nordisk Nonalcoholic Steatohepatitis Treatment Product Portfolio
  48. 8.8.5 Novo Nordisk Recent Developments
  49. 8.9 Vivus
  50. 8.9.1 Vivus Company Information
  51. 8.9.2 Vivus Business Overview
  52. 8.9.3 Vivus Nonalcoholic Steatohepatitis Treatment Revenue and Gross Margin (2021-2026)
  53. 8.9.4 Vivus Nonalcoholic Steatohepatitis Treatment Product Portfolio
  54. 8.9.5 Vivus Recent Developments
  55. 8.10 AstraZeneca
  56. 8.10.1 AstraZeneca Company Information
  57. 8.10.2 AstraZeneca Business Overview
  58. 8.10.3 AstraZeneca Nonalcoholic Steatohepatitis Treatment Revenue and Gross Margin (2021-2026)
  59. 8.10.4 AstraZeneca Nonalcoholic Steatohepatitis Treatment Product Portfolio
  60. 8.10.5 AstraZeneca Recent Developments
  61. 8.11 GSK
  62. 8.11.1 GSK Company Information
  63. 8.11.2 GSK Business Overview
  64. 8.11.3 GSK Nonalcoholic Steatohepatitis Treatment Revenue and Gross Margin (2021-2026)
  65. 8.11.4 GSK Nonalcoholic Steatohepatitis Treatment Product Portfolio
  66. 8.11.5 GSK Recent Developments
  67. 8.12 Roche
  68. 8.12.1 Roche Company Information
  69. 8.12.2 Roche Business Overview
  70. 8.12.3 Roche Nonalcoholic Steatohepatitis Treatment Revenue and Gross Margin (2021-2026)
  71. 8.12.4 Roche Nonalcoholic Steatohepatitis Treatment Product Portfolio
  72. 8.12.5 Roche Recent Developments
9 Concluding Insights
    10 Appendix
    1. 10.1 Reasons for Doing This Study
    2. 10.2 Research Methodology
    3. 10.3 Research Process
    4. 10.4 Authors List of This Report
    5. 10.5 Data Source
    6. 10.5.1 Secondary Sources
    7. 10.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst